PMID- 38456694
OWN - NLM
STAT- Publisher
LR  - 20240308
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
DP  - 2024 Mar 8
TI  - Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk 
      follicular and indolent non-Hodgkin lymphoma.
PG  - 1-6
LID - 10.1080/10428194.2024.2325636 [doi]
AB  - Lenalidomide and rituximab (R(2)) is an effective frontline treatment for 
      patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the 
      safety and efficacy of addition of the proteasome inhibitor ixazomib to R(2) for 
      treatment of iNHL through a phase I/II clinical trial for high-risk patients. 
      Twenty patients were enrolled, 18 were treated. The target dose of ixazomib 4 mg 
      weekly was achieved during dose escalation. The most common treatment-related 
      adverse events (AEs) were low grade gastrointestinal, rash, neuropathy, and 
      myalgia/arthralgia. There were 33% grade 2 and 17% grade 3 infections. With 
      median follow-up of 5.2 years, four patients discontinued treatment due to 
      lymphoma progression. Best overall response rate (ORR) was 61.2% [55.6% CR, 5.6% 
      PR): 22.2% had stable disease and 16.7% had disease progression. Kaplan-Meier 
      estimates of progression free and overall survival (OS) were 73% and 87% at 
      36 months, respectively. R(2) can safely be combined with ixazomib for 
      treatment-naive iNHL patients.
FAU - Hill, Brian T
AU  - Hill BT
AUID- ORCID: 0000-0001-8781-3327
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Chen, Yanwen
AU  - Chen Y
AUID- ORCID: 0000-0003-3147-0278
AD  - Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Jagadeesh, Deepa
AU  - Jagadeesh D
AUID- ORCID: 0000-0002-1772-0659
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Dean, Robert
AU  - Dean R
AUID- ORCID: 0000-0003-2559-563X
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Koc, Omer
AU  - Koc O
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Boughan, Kirsten
AU  - Boughan K
AD  - Case Western Reserve University School of Medicine, University Hospitals, 
      Cleveland, OH, USA.
FAU - Cooper, Brenda
AU  - Cooper B
AUID- ORCID: 0000-0001-9376-9377
AD  - Case Western Reserve University School of Medicine, University Hospitals, 
      Cleveland, OH, USA.
FAU - Pohlman, Brad
AU  - Pohlman B
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Caimi, Paolo
AU  - Caimi P
AUID- ORCID: 0000-0003-1436-0464
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
FAU - Smith, Mitchell R
AU  - Smith MR
AUID- ORCID: 0000-0003-1428-8765
AD  - Department of Hematology and Medical Oncology, Taussig Cancer Institute, 
      Cleveland Clinic, Cleveland, OH, USA.
AD  - The Follicular Lymphoma Foundation, Washington, DC, USA.
LA  - eng
PT  - Journal Article
DEP - 20240308
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
OTO - NOTNLM
OT  - Rituximab
OT  - follicular lymphoma
OT  - indolent lymphoma
OT  - ixazomib
OT  - lenalidomide
EDAT- 2024/03/08 12:43
MHDA- 2024/03/08 12:43
CRDT- 2024/03/08 09:03
PHST- 2024/03/08 12:43 [medline]
PHST- 2024/03/08 12:43 [pubmed]
PHST- 2024/03/08 09:03 [entrez]
AID - 10.1080/10428194.2024.2325636 [doi]
PST - aheadofprint
SO  - Leuk Lymphoma. 2024 Mar 8:1-6. doi: 10.1080/10428194.2024.2325636.